Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

Sanofi’s third-quarter results showed the company’s pharma and vaccines businesses grew faster and were more profitable than its consumer-health unit Opella.

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

While the inquiry gets most things right, as vaccine experts, we argue the government response should be broadened in three ...

Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus ...

Investing.com -- Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales ...

Vaccines sales rose a currency-adjusted 25.5% to 3.8 billion euros in the quarter, ahead of a 3.2 billion euro analyst consensus. Sanofi is nearing a sale of a 50% stake in its consumer unit ...

The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.